The Australian Competition and Consumer Commission has won an injunction to stop Virtus from completing the purchase of rival Adora Fertility until a court has ruled on the competition regulator’s challenge to the acquisition.
IVF provider Virtus Health would be “the author of its own fate” if its proposed acquisition of rival Adora Fertility flopped, a judge has said in hearing the ACCC’s bid for a temporary injunction blocking completion of the planned purchase.
The 64-year-old son of former Qantas chairman Sir Lenox Hewitt, who sued the airline for age discrimination earlier this year, has taken the company to court again alleging he’s owed over $90,000 in compensation.
Seven Network is seeking to remove several trade marks and logos registered to 7-Eleven, in a lawsuit filed just three months after the convenience store won its bid to have the broadcaster’s ‘7NOW’ mark removed.
The ACCC has won an interim injunction blocking IVF provider Virtus Health from completing its purchase of rival Adora Fertility on Friday.
Five enforcement officers of the Australian Competition and Consumer Commission will be cross-examined by lawyers for banks facing price fixing charges over their conduct following ANZ’s $2.5 billion capital raising six years ago.
A judge overseeing a cartel case over a $2.5 billion ANZ share placement has granted ANZ’s bid for unredacted documents which the bank says will support its claims that the case should be permanently stayed because of improper dealings between whistleblower JPMorgan, ASIC and the ACCC.
A judge has criticised Qantas and the Transport Workers’ Union for their “not particularly helpful” public comments about whether or not ground staff will be reinstated upon resolution of their long-running outsourcing dispute.
As Australia’s largest cities prepare to emerge from lockdown, law firms are doubling down on their efforts to vaccinate staff, with some going so far as to implement a ‘no jab, no office’ policy.
An Australian generic drug manufacturer has struck back at patent lawsuit by Swiss pharmaceutical company Biogen, alleging a patent for MS drug Tecfidera is invalid and a that a patent term extension for the drug was wrongly granted.